Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T15:56:11.574Z.
Consensus retrieved: 2026-10-06T11:06:10.627Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:56:11.574Z.
Quote observation: 2026-10-06T15:54:49.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b2d28e84da0c930e75004ae600b803967d1975629f72cad3bf33ad83c9831f21
Forward PE Ratio (N/A) = Dated Quote Price ($7.69) / Consensus Forward EPS ($-7.08)
FORWARD PE RATIO
N/A
Eikon Therapeutics, Inc. Common Stock
Market Cap
$416.59M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Eikon Therapeutics, Inc. Common Stock (EIKN) | $416.59M | N/A |
| Neurogene Inc. (NGNE)vs › | $415.36M | N/A |
| Myriad Genetics, Inc. (MYGN)vs › | $411.32M | N/A |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $410.94M | N/A |
| Prothena Corporation plc (PRTA)vs › | $422.75M | 73.41 |
| Shoulder Innovations, Inc. (SI)vs › | $409.27M | N/A |
| Carlsmed, Inc. (CARL)vs › | $408.73M | N/A |
| MapLight Therapeutics, Inc. (MPLT)vs › | $397.84M | N/A |
| REGENXBIO Inc. (RGNX)vs › | $396.61M | N/A |
| Editas Medicine, Inc. (EDIT)vs › | $438.47M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $7.69, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-7.08 | $-7.51 – $-6.57 | 5 | n/m |
| 2027-12-31 | $-7.08 | $-8.27 – $-5.80 | 5 | n/m |
| 2028-12-31 | $-6.33 | $-8.23 – $-5.11 | 5 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
